الفهرس 
Anatomy of the RectumOnly 14 pages are availabe for public view
 |  | from | 67 |  |  |
| | | from | 67 | | |
Abstract
Background: Treatment response varies signifcantly among rectal cancer patients. Tumor can show complete regression, stationary appearance, or even tumour progression during the treatment. It is also widely known that the rate of local recurrence is variable. Precise risk stratifcation of tumor aggressiveness is required for better per patient tailored treatment plan and predicting the overall prognosis of rectal cancer patients The aim of this study was to assess diferent parameters of baseline [18F] fuorodeoxyglucose positron emission tomography/computed tomography [(18F) FDG-PET/CT] as a non-invasive tool in predicting aggressiveness of the rectal cancer. Results: Overall, 33 patients were included [19 moderately diferentiated adenocarcinoma, 10 poorly diferentiated adenocarcinoma and 4 mucinous adenocarcinomas (MAC)]. SUV estimates (SUV max, SUV mean) were greater in the moderately adenocarcinoma group (p=0.003 and p=0.019, respectively). MTV and TLG values were similar between the three histopathological groups (p=0.763 and p=0.701, respectively). There was no correlation between SUVmax of primary tumor and MTV (r=0.034; p=0.849). However, SUVmax and TLG were signifcantly correlated (r=0.517; p=0.002). Strong correlation between tumor size and MTV (r=0.489; p=0.003), and TLG (r=0.506; p=0.003) were observed. No signifcant association was found between MTV and TLG and the clinical stage of rectal cancer. Conclusion: Baseline 18F-FDG PET/CT parameters cannot be used alone as a non-invasive diagnostic technique in assessing aggressiveness and prognosis in patients with primary rectal cancer, and further clinical studies are needed before considering the prognostic role of FDG-PET/CT in rectal cancer.